In this issue:
- ICIs in melanoma and pre-existing autoimmune disease
- Trastuzumab during pregnancy
- Early anti-PD-1 discontinuation in advanced melanoma
- Nivolumab and ipilimumab for advanced rare genitourinary malignancies
- Oral side effects of ICIs
- Antibiotic and ICI response
- Low-dose pembrolizumab for advanced NSCLC
- Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
- Health-related QOL in metastatic CRC: first-line pembrolizumab vs. chemotherapy
- Pembrolizumab vs. chemotherapy for metastatic triple-negative breast cancer
Download PDF